KNSA - Kiniksa Pharmaceuticals Ltd Class A (Healthcare: Biotechnology) Projected Earnings Date: 2025-10-28    (Delayed quote data   2025-09-16)
Last
 35.77		 Change
 ⇓ -0.79   (-2.16%)		 Volume
  274,225
Open
 36.57		 High
 36.64		 Low
 35.54
8EMA (Daily)
 36.17		 40EMA (Daily)
 33.43		 50EMA (Daily)
 32.72		 STO (Daily)
 82.069		 MACD Hist (Daily)
 -0.052
8EMA (Weekly)
 34.015		 40EMA (Weekly)
 27.65		 50EMA (Weekly)
 26.66		 STO (Weekly)
 92.331		 MACD Hist (Weekly)
 1.162
Company Profile
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com